Cilazapril (Synonyms: Ro 31-2848) |
|
Catalog No.GC12859
|
ACE inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 88768-40-5
Sample solution is provided at 25 µL, 10mM.
Cilazapril is an inhibitor of angiotensin converting enzyme (ACE) with IC50 value of 1.93nM [1].
Cilazapril is a monoethyl prodrug of cilazaprilat. The latter shows an IC50 value of 1.93nM to rabbit lung ACE when using Hip-His-Leu substrate in vitro. Cilazaprilat is most potent among all the ACE inhibitors when the ACE is from rabbit lung, human plasma, hog kidney or human lung. Cilazaprilat is specific. It shows no inhibition to a variety of lipolytic and proteolytic enzymes even the concentration of it is up to more than 10000 fold higher than its IC50 value. Cilazapril and cilazaprilat also show inhibition of the angiotensin I (AI) pressor response with ED50 vallues of 0.44 and 0.06 mmol/kg. In addition, when cilazapril is treated as an antihypertensive drug, the maximum decrease in blood pressure relative to the control is 110mmHg on day 21 [1].
References:
[1] Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27
| Cas No. | 88768-40-5 | SDF | |
| Synonyms | Ro 31-2848 | ||
| Chemical Name | (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid | ||
| Canonical SMILES | CCOC(=O)C(CCC1=CC=CC=C1)NC2CCCN3CCCC(N3C2=O)C(=O)O | ||
| Formula | C22H31N3O5 | M.Wt | 417.5 |
| Solubility | Chloroform: slightly soluble,Ethanol: slightly soluble,Methanol: slightly soluble | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3952 mL | 11.976 mL | 23.9521 mL |
| 5 mM | 479 μL | 2.3952 mL | 4.7904 mL |
| 10 mM | 239.5 μL | 1.1976 mL | 2.3952 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)















